Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.

Start Date18 Dec 2030

Sponsor / Collaborator

Actuate Therapeutics, Inc.

NCT07229339

/ Not yet recruitingPhase 2IIT

Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations

This phase II trial tests how well zipalertinib with carboplatin and pemetrexed works in treating stage II-IIIB non small cell lung cancer. that can be removed by surgery (resectable). Zipalertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Giving zipalertinib with carboplatin and pemetrexed may kill more tumor cells in patients with resectable, stage II-IIIB non-small cell lung cancer.

Start Date01 Jun 2027

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+1]

NCT07346196

/ Not yet recruitingPhase 2IIT

A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.

Start Date07 Feb 2027

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Carboplatin

100 Translational Medicine associated with Carboplatin

100 Patents (Medical) associated with Carboplatin

24,696

Literatures (Medical) associated with Carboplatin

31 Dec 2026·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

Author: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

31 Dec 2026·CANCER BIOLOGY & THERAPY

Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids

Article

Author: Tomas, Emily J. ; Davis, Jennifer ; Ramos Valdes, Yudith ; Shepherd, Trevor G.

BACKGROUND:

PARP inhibitors (PARPis) are new targeted agents that exploit homologous recombination DNA repair deficiencies (HRDs), which are present in 50% of high-grade serous carcinoma (HGSC) cases. Currently, olaparib is approved as maintenance therapy for BRCA1/2-mutated HGSC, and niraparib is approved for platinum-sensitive recurrent disease. However, research is currently expanding their potential as front-line agents or in combination with carboplatin, a standard HGSC chemotherapeutic.

METHODS:

Immortalized ovarian cancer (iOvCa) cell lines, developed from HGSC patient ascites, were treated with carboplatin, olaparib and niraparib to determine their sensitivity. Immunofluorescence analysis of RAD51 was conducted for HRD testing of all the cell lines. The cell lines were cultured as three-dimensional organoids and spheroids to mimic tumor growth and metastasis, respectively, and then treated to assess the effects of different drug combinations.

RESULTS:

The half-maximal inhibitory concentrations of olaparib and niraparib varied across our iOvCa cell lines, with iOvCa195 BRCA1-mutant line exhibiting the expected high sensitivity to both PARPis. Direct combination of carboplatin with olaparib or niraparib enhanced cell killing, yet achieved cell viability levels to those of carboplatin alone. In sequential experiments, carboplatin followed by either PARPi or vice versa showed no significant difference in cell viability to carboplatin alone, except in iOvCa195 organoids when treated with a PARPi first.

CONCLUSIONS:

Overall, first-line carboplatin treatment remains ideal, yet there may be select utility for PARPi prior to chemotherapy. Using patient-derived tumor models such as spheroids and organoids may provide insights for on-going and future clinical trials to enhance therapeutic outcomes for HGSC patients.

01 Jun 2026·JOURNAL OF INORGANIC BIOCHEMISTRY

Selective tumor accumulation as a route to precision medicine for platinum anticancer drugs

Article

Author: Peterson, Erica J ; Farrell, Nicholas P

This brief review summarizes our work showing that glycosaminoglycans (GAGs) are mediators of platinum complex cellular accumulation. Especially, there is an inverse relationship whereby charged polynuclear platinum complexes exemplified by BBR3464 and BBR3571 show enhanced tumor accumulation and antitumor efficacy in presence of a high level of GAGs whereas the inverse relationship occurs for the neutral mononuclear carboplatin. These results add to our understanding of the tumor uptake of platinum anticancer drugs and suggest avenues toward precision medicine for platinums based on patient stratification.

1,183

News (Medical) associated with Carboplatin

07 Apr 2026

·allsci.com

Immedica’s lurbinectedin-atezolizumab combination gets CHMP nod for ES-SCLC maintenance

Sweden-based biopharma Immedica revealed that lurbinectedin (Zepzelca) combined with atezolizumab has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as first-line maintenance therapy for extensive-stage small cell lung cancer, moving the combination closer to becoming the first approved regimen to improve survival beyond checkpoint inhibitor monotherapy in this setting. The opinion is based on data from the Phase III IMforte trial, a randomized, open-label study enrolling adults with ES-SCLC whose disease had not progressed following four cycles of induction therapy with atezolizumab, carboplatin, and etoposide. In IMforte, the lurbinectedin-atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared with atezolizumab maintenance alone. Measured from the point of randomization, median overall survival was 13.2 months versus 10.6 months (HR 0.73; 95% CI: 0.57–0.95; p=0.0174), and median progression-free survival by independent assessment was 5.4 months versus 2.1 months (HR 0.54; 95% CI: 0.43–0.67; p<0.0001). The data were presented at the 2025 ASCO annual meeting and published simultaneously in The Lancet. Safety was consistent with the known profiles of both agents. The CHMP opinion now passes to the European Commission for a final marketing authorization decision covering the EU. Before the FDA approved lurbinectedin plus atezolizumab in October 2025, the maintenance phase of ES-SCLC treatment was defined by continuation of a single checkpoint inhibitor — Roche’s PD-L1 target datezolizumab (Tecentriq) following the IMpower133 regimen, or AstraZeneca’s PD-L1 durvalumab (Imfinzi) following the CASPIAN regimen. Both approaches offered modest survival benefit over chemotherapy alone but left the maintenance window largely unchallenged. The IMforte control arm, with a median PFS of 2.1 months on atezolizumab alone, illustrates how quickly patients progressed even after responding to induction. Lurbinectedin is a marine-derived small molecule that inhibits RNA polymerase II-dependent transcription, suppressing oncogenic transcription programs in tumor cells and, according to PharmaMar’s characterization, also downregulating cytokine production in tumor-associated macrophages. The mechanistic rationale for pairing it with a PD-L1 inhibitor rests on the premise that transcription inhibition and immune checkpoint blockade address distinct and potentially complementary tumor escape mechanisms. Whether this dual targeting accounts for the observed survival benefit, or whether the cytotoxic activity of lurbinectedin is the primary driver, is not established from the press release data alone. The survival gain — approximately 2.6 months in median OS and 3.3 months in median PFS — is statistically significant and consistent across both endpoints, which strengthens the signal. The OS hazard ratio of 0.73, however, sits at the wider end of what oncologists typically consider a practice-defining benefit in a maintenance setting, and the confidence interval (0.57–0.95) approaches 1.0. The PFS benefit is more pronounced (HR 0.54), but PFS improvements in SCLC have not always translated proportionally to OS gains, and the absolute OS difference here is modest. The competitive framing is also shifting. Tarlatamab, a DLL3×CD3 T-cell engager developed by Amgen, is in Phase III evaluation in relapsed SCLC benchmarked against standard-of-care chemotherapy options that include lurbinectedin. That program operates in a different line of therapy and uses a mechanistically distinct approach — immune redirection rather than transcription inhibition — but it signals that the SCLC treatment landscape is being contested across multiple modalities simultaneously. Cross-trial comparisons are limited by differences in patient populations, lines of therapy, and trial design, and no head-to-head data exist between these approaches in any shared setting. For Immedica, the CHMP opinion covers its distribution territories in the Nordics, UK and Ireland, Central and Eastern Europe, and the Middle East and North Africa, under a partnership with PharmaMar, which originated the compound. Jazz Pharmaceuticals holds US rights and sponsored the FDA approval. The commercial structure means that the EU authorization, once granted by the European Commission, will be executed across multiple regional partners rather than a single entity — a distribution model that may affect how quickly the combination reaches patients in different healthcare systems. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

03 Apr 2026

·allsci.com

Alphamab’s HER2 BsAb anbenitamab meets primary endpoint in Phase III HER2-positive breast cancer trial

Alphamab Oncology (HKEX: 9966) revealed that anbenitamab (KN026), a bispecific anti-HER2 antibody, met its primary endpoint in the Phase III Neo-Healer trial evaluating neoadjuvant treatment of early or locally advanced HER2-positive breast cancer, with the company describing the total pathological complete response (tpCR) result as both statistically and clinically significant versus the current standard of care. Neo-Healer (KN026-004) is a randomized, open-label, multicenter Phase III study planned to enroll approximately 520 patients with early or locally advanced HER2+ breast cancer, assigned 1:1 to receive KN026 plus albumin-bound docetaxel (HB1801) ± carboplatin or trastuzumab plus pertuzumab plus docetaxel ± carboplatin, with total pathological complete response assessed by a blinded independent review committee as the primary endpoint. No numerical tpCR rates, confidence intervals, or p-values were disclosed. The announcement stated only that KN026 in combination with HB1801 ± carboplatin “significantly improved” tpCR compared with the standard regimen, with full data to be presented at an international conference. The absence of quantitative results limits any assessment of effect size at this stage. Safety data were not reported. Alphamab’s HER2 bispecific engineering Anbenitamab is engineered using Alphamab’s CRIB (Charge Repulsion Induced Bispecific) platform and binds two non-overlapping epitopes on HER2 simultaneously, blocking downstream signaling while enhancing antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and receptor downregulation. The design effectively consolidates the biological roles of trastuzumab and pertuzumab — which target distinct HER2 epitopes — into a single molecule. The experimental arm also replaces standard docetaxel with HB1801, CSPC Group’s albumin-bound docetaxel formulation, which encapsulates the active drug in human serum albumin, eliminating the polysorbate 80 and ethanol solvents associated with hypersensitivity reactions and premedication requirements. Competitive context The neoadjuvant HER2+ breast cancer setting is one where the limitations of current therapy are quantifiable. Trastuzumab plus pertuzumab combined with chemotherapy — the THP/TCbHP regimen — achieves tpCR in roughly half of patients with early or locally advanced disease. Patients who do not achieve tpCR face a materially worse prognosis and are typically escalated to adjuvant ado-trastuzumab emtansine (T-DM1). A bispecific antibody that raises the tpCR ceiling would, in principle, reduce downstream escalation requirements, though the Neo-Healer data needed to substantiate that argument have not yet been released. The competitive framing matters here. The trial’s active comparator is trastuzumab plus pertuzumab plus docetaxel — which is itself the globally established standard and the benchmark against which Roche’s Phesgo, the fixed-dose subcutaneous co-formulation of both antibodies, has positioned its convenience advantage. KN026 is not competing on route of administration but on mechanistic consolidation and, if the data support it, on efficacy magnitude. The absolute tpCR improvement will need to be evaluated carefully when full results are published. KN026’s regulatory trajectory is more advanced in gastric cancer than in breast cancer. The China National Medical Products Administration accepted a new drug application for KN026 in combination with chemotherapy for second-line or above HER2+ gastric or gastroesophageal junction cancer in September 2025, and that application remains under review. The US FDA has granted KN026 orphan drug designation for HER2+ or HER2-low gastric cancer. The NMPA also granted breakthrough therapy designation for the same gastric cancer indication. None of these designations extend to breast cancer, where KN026 remains investigational. The breast cancer program is structured as a multi-indication effort. Alongside Neo-Healer, Alphamab and its partner JMT-Bio — a subsidiary of CSPC Pharmaceutical Group (HKEX: 1093), which holds exclusive mainland China development and commercialization rights for KN026 in breast and gastric cancer — are running registrational trials in first-line HER2+ breast cancer and in the adjuvant HER2+ breast cancer setting. A Phase III adjuvant study (NCT07441460) is listed on AllSci as not yet recruiting. The partnership structure is relevant to the commercial picture. JMT-Bio’s rights cover mainland China; Alphamab retains rights elsewhere. The primary near-term market for Neo-Healer data, if regulatory submissions follow, would be China, where HER2+ breast cancer accounts for approximately 20%-30% of breast cancer cases and where roughly 75% of patients present at early or locally advanced stage — the exact population Neo-Healer enrolled. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Orphan DrugBreakthrough TherapyClinical ResultFast Track

02 Apr 2026

·www.prnewswire.com

Bright Path Applauds Presidential Proclamation Imposing Tariffs on Imported Pharmaceuticals

DARPA-validated company is already manufacturing essential medicine APIs entirely on U.S. soil MESA, Ariz., April 2, 2026 /PRNewswire/ -- Bright Path, a U.S.-based advanced pharmaceutical manufacturer, today welcomed President Trump's proclamation imposing tariffs of up to 100 percent on imported patented pharmaceuticals and active pharmaceutical ingredients (APIs) under Section 232 of the Trade Expansion Act. The proclamation, which the President signed today citing threats to national security from foreign pharmaceutical dependence, validates the mission Bright Path has been executing for six years: building a fully domestic manufacturing capability for essential medicines with zero foreign inputs or dependencies. "Today's action sends the clearest signal yet that America is serious about manufacturing its own medicines," said Tony Quiñones, Founder and CEO of Bright Path. "We didn't wait for tariffs to start building. We've spent six years designing our own reactors, writing our own software, and proving that the United States can produce its own essential medicines. Our factory is built and our technology is validated. We've already done what most companies are still promising." The presidential proclamation finds that pharmaceutical imports threaten U.S. national security, noting that approximately 53 percent of patented pharmaceutical products distributed domestically are produced outside the country and only 15 percent of active pharmaceutical ingredients are manufactured in the United States. The proclamation establishes a 100 percent ad valorem duty on imported patented pharmaceuticals and APIs, with reduced rates for companies that commit to onshoring production to U.S. soil. Tariffs take effect beginning July 31, 2026. Bright Path's manufacturing platform uses the company's patented Spinning Tube-in-Tube (STT®) continuous flow reactor technology, which the company designs, fabricates, and assembles entirely in-house. STT® technology can produce medicines in less time, at lower cost, and at higher quality than traditional batch approaches, while also enabling faster regulatory review and rapid changeover between drug syntheses. The platform has been validated through the Defense Advanced Research Projects Agency (DARPA) EQUIP-A-Pharma program, under which Bright Path has achieved all contract milestones across three successive awards. The company has filed Abbreviated New Drug Applications (ANDAs) with the FDA for lidocaine and carboplatin, two essential hospital medicines that appear on the FDA drug shortage list. The company's advanced manufacturing platform is capable of addressing 87 percent of the World Health Organization's Essential Medicines List, producing over 13.4 million vials per year at full capacity, and achieving 281 percent higher yield than conventional batch manufacturing. The entire production process, from key starting materials through finished dosage form, takes place at the company's Falcon Field facility in Mesa, Arizona. "The President's proclamation makes clear what we've known for years: depending on foreign supply chains for life-saving medicines is a national security risk we can no longer afford," Quiñones continued. "More than 80 percent of the active ingredients in our essential medicines come from overseas, much of it from countries that may not have America's best interests in mind. Drug shortages emerge fast. Our manufacturing has to be just as fast, and our regulatory frameworks need to keep pace with the technology. We are fully operational and ready to scale." The proclamation establishes a tiered tariff structure that incentivizes domestic production, offering reduced duty rates for companies with approved onshoring plans and preferential treatment for those that commit to manufacturing pharmaceuticals and APIs on American soil. Bright Path's Mesa facility represents exactly the kind of domestic manufacturing infrastructure the proclamation is designed to encourage, with a fully integrated production line that eliminates reliance on foreign suppliers at every stage of the pharmaceutical supply chain. Bright Path has partnered with DARPA and the Administration for Strategic Preparedness and Response (ASPR) through the Center for Industrial Base Management and Supply Chain (IBMSC). The company is a member of the FDA's Emerging Technology Program and has submitted its application to the BioMaP Consortium for expanded domestic manufacturing capacity. About Bright Path Bright Path's manufacturing platform uses the company's patented Spinning Tube-in-Tube (STT®) continuous flow reactor technology, which the company designs, fabricates, and assembles entirely in-house. Bright Path is a direct recipient and partner of the Defense Advanced Research Projects Agency (DARPA), which selected the company for its EQUIP-A-Pharma program to advance domestic pharmaceutical manufacturing capability. The platform has been validated through that program, under which Bright Path has achieved all contract milestones across three successive awards. The company has filed Abbreviated New Drug Applications (ANDAs) with the FDA for lidocaine and carboplatin, two essential hospital medicines that appear on the FDA drug shortage list. Contact: Bruce Fryer, [email protected] SOURCE Bright Path 21% more press release views with Request a Demo

100 Deals associated with Carboplatin

External Link

KEGG	Wiki	ATC	Drug Bank
D01363	Carboplatin	L01XA02	DB00958

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Recurrent ovarian cancer	United States	Avyxa Pharma	08 Aug 2025
Endometrial Carcinoma	Japan	Clinigen KK	24 Jun 2024
Uterine Neoplasms	Japan	CHEPLAPHARM Arzneimittel GmbH	24 Jun 2024
Breast Cancer	Japan	Clinigen KK	25 Nov 2011
Breast Cancer	Japan	CHEPLAPHARM Arzneimittel GmbH	25 Nov 2011
Breast Cancer	Japan	Bristol-Myers Squibb KK	25 Nov 2011
Ovarian Epithelial Carcinoma	Brazil	Libbs Farmacêutica Ltda.	20 Nov 2006
Childhood Germ Cell Tumor	Japan	CHEPLAPHARM Arzneimittel GmbH	15 Sep 2005
Ewing Sarcoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Ewing Sarcoma	Japan	Clinigen KK	15 Sep 2005
Hepatoblastoma	Japan	Clinigen KK	15 Sep 2005
Hepatoblastoma	Japan	CHEPLAPHARM Arzneimittel GmbH	15 Sep 2005
Hepatoblastoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Neuroblastoma	Japan	CHEPLAPHARM Arzneimittel GmbH	15 Sep 2005
Neuroblastoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Neuroblastoma	Japan	Clinigen KK	15 Sep 2005
Recurrent Ewing Sarcoma	Japan	CHEPLAPHARM Arzneimittel GmbH	15 Sep 2005
Refractory Ewing Sarcoma	Japan	CHEPLAPHARM Arzneimittel GmbH	15 Sep 2005
Retinoblastoma	Japan	Clinigen KK	15 Sep 2005
Retinoblastoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 3	United States	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Austria	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Belgium	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Denmark	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	France	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Germany	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Italy	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Netherlands	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Spain	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Switzerland	CarThera SAS	29 Jan 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SWOG S0819 (AACR2026)	Phase 3	Non-Small Cell Lung Cancer Serial CTRS	1,275	Cetuximab + carboplatin/paclitaxel	jchoqbcmqk(jyhrhkysbk) = BOR achieved 35% (33–37%) power omfzzmwafg (wcurfavgyw ) View more	Positive	20 Apr 2026
				Bevacizumab + cetuximab + carboplatin/paclitaxel
NCT02402920 (CTgov)	Phase 1	Small cell lung cancer limited stage \| Extensive stage Small Cell Lung Cancer \| Neuroendocrine Tumors	83	platinum+etoposide+pembrolizumab (LS-SCLC (Limited-Stage Small Cell Lung Cancer))	xvdempyrpz = gpatkoxfaq qtnznenjel (euwsirfczo, gcryzjrcof - bfcmlwmqti) View more	-	10 Mar 2026
				pembrolizumab (ES-SCLC (Extended-Stage Small Cell Lung Cancer))	xvdempyrpz = wytzwmsldl qtnznenjel (euwsirfczo, tnqulcayxi - mmlypunzmh) View more
NCT02031250 (CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck \| Locally Advanced Head and Neck Squamous Cell Carcinoma	106	IMRT (Intensity-Modulated Radiation Therapy)+Carboplatin+cisplatin (Control Arm)	lndygktvdc(yuymzhnmkx) = ueffujbhvs dkxjswazen (gdrfxclvnk, mchtyllhga - brrmaytfiz) View more	-	02 Mar 2026
				IMRT (Intensity-Modulated Radiation Therapy)+Carboplatin+cisplatin (Boost Arm)	lndygktvdc(yuymzhnmkx) = xjltdqipnm dkxjswazen (gdrfxclvnk, dfjhigvmid - ayyrgcqerl) View more
ESGO2026	Not Applicable	Endometrial Carcinoma Adjuvant	63	Carboplatin with paclitaxel (CP)	esqdzdwzvo(teekcuocsp) = kvyukobhvt mobuceynic (hkjtixsbgb ) View more	Positive	28 Feb 2026
ESGO2026	Not Applicable	Ovarian Cancer	95	carboplatin-paclitaxel chemotherapy	bkmuoxrohi(qlrlxbzdnu) = qfagfflzsd vomlnfrtwg (nmltqzemen, 6 - 12)	Positive	28 Feb 2026
INTERLACE (ESGO2026)	Not Applicable	Locally Advanced Cervical Carcinoma	32	CarboplatinCisplatinin + Paclitaxel + CarboplatinCisplatinPaclitaxel	wxqgzhshho(nschohjrmy) = ohjjyqgeie spmnqmzfxe (deduoyxpjp )	Positive	28 Feb 2026
ESGO2026	Not Applicable	Endometrial Carcinoma	36	Weekly carboplatin-paclitaxel (TC) (Frail patients unsuitable for 3-weekly chemotherapy)	gkeifhfizh(ebowfvjaxo) = Weekly TC was overall well tolerated, with low rates of neutropenia(11%), anaemia(22%), thrombocytopenia(3%), fatigue(6%), neurotoxicity(8%) and gastrointestinal toxicity(3%), and no cutaneous events rinyelgwlq (baduofrcpu )	Positive	28 Feb 2026
CIPHER (ASCO_GU2026)	Phase 2	Metastatic castration-resistant prostate cancer HRR	39	carboplatin	jfkifidonb(uwjhsqocin) = msqbsnjgcq vsticglzrr (huggdxmbam ) View more	Positive	26 Feb 2026
IFUCA (ASCO_GU2026)	Not Applicable	Locally Advanced Urothelial Carcinoma First line FGFR3 alterations	191	Platinum-based chemotherapy	nfqdzndihr(csxdysyaqg) = myxaacrfdr bqcwrjpqxp (moeioduhth ) View more	Negative	26 Feb 2026
				Immune checkpoint inhibitor	nfqdzndihr(csxdysyaqg) = nlmjgzukoh bqcwrjpqxp (moeioduhth ) View more
ASCO_GU2026	Not Applicable	Prostatic Cancer First line	36	Carboplatin-docetaxel (CARBO-DOCE) (CR-AVPC)	iedtkdvcnm(lpmxcqjkpe) = 77.8% had grade ≥3 adverse events; commonly neutropenia (44.4%), anaemia (30.6%), and fatigue (13.9%). yppdwrmvba (gkugjdnifz ) View more	Positive	26 Feb 2026
				Carboplatin-docetaxel (CARBO-DOCE) (DN-AVPC)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis